Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 3, 1996, Pages 332-340

  Fernández De Gatta, Ma Del Mar ^b   Calvo, Ma Victoria ^a   Hernández, Jesus M ^b   Caballero, Dolores ^b   San Miguel, Jesus F ^b   Domínguez Gil, Alfonso ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; ARTICLE; BLOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG MONITORING; ECONOMICS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; COST-BENEFIT ANALYSIS; DRUG MONITORING; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VANCOMYCIN;

EID: 10244226708     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90060-0     Document Type: Article

References (31)

1. Wade J. Antibiotic therapy for the febrile granulocytopenic cancer patient: combination versus monotherapy. Rev Infect Dis 1989;(suppl 7):1572-81.
2. Smith SR, Cheesbroug J, Harding I, Davies JM. Role of glycopeptide antibiotics in the treatment of febrile neutropenic patients. Br J Haematol 1990;76(suppl 2):54-6.
3. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
4. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;18:30-5.
5. Matzke GR. Vancomycin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver: Applied Therapeutics, 1992:1-31.
6. Dufful SB, Begg EJ. Vancomycin toxicity: what is the evidence for dose dependency? Adverse Drug React Toxicol Rev 1994;13:103-14.
7. Tonkin AL, Bochner F. Therapeutic drug monitoring and patient outcome: a review of the issues. Clin Pharmacokinet 1994;27:169-74.
8. Vozeh S. Cost-effectiveness of therapeutic drug monitoring. Clin Pharmacokinet 1987;13:131-40.
9. Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin Pharm 1987;6:652-4.
10. Rodvold KA, Zofuka H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified?. Clin Pharm 1987;6:655-8.
11. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993;27:594-8.
12. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994;18:533-43.
13. Fernandez de Gatta MM, Fruns I, Hernandez JM, Caballero D, San Miguel JF, Martinez-Lanao JM, et al. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm 1993;12:515-20.
14. Perkins MW, Dasta JF, DeHaven B. Physiologic implications of mechanical ventilation on pharmacokinetics. Ann Pharmacother 1989;23:316-23.
15. Halloway JJ, Smith CR, Moore RD, Feroli R, Lietman PS. Comparative cost effectiveness of gentamicin and tobramycin. Ann Intern Med 1984;101:764-9.
16. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987;83:1091-7.
17. Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990;10:378-82.
18. Salama SE, Rotstein C. Prospective assessment of nephrotoxicity with concomitant aminoglycoside and vancomycin therapy. Can J Hosp Pharm 1993; 46:53-9.
19. Bootman JL, Wertheimer AI, Zaske D, Rowland C. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost-benefit analysis. J Pharm Sci 1979;68:267-72.
20. Destache CJ, Meyer SK, Bittner MJ, Hermann KG. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drag Monit 1990;12:419-26.
21. Ho KKL, Thiressen JJ, Bryson SM, Greenberg ML, Einarson TR, Leson CL. Challenges in comparing treatment outcome from a prospective with that of a retrospective study: assessing the merit of gentamicin therapeutic drug monitoring in pediatric oncology. Ther Drug Monit 1994;16:238-47.
22. Mckormack JP, Lynd LD, Pfeifer NM. Vancomycin cost containment through a therapeutic and pharmacokinetic drug monitoring service. Can J Hosp Pharm 1989,42:3-9.
23. Garrelts JC, Dale Horst W, Silkey B, Gagnon S. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy 1994;14:438-45.
24. Kureishi A, Jewesson PJ, Rubinger M, Cole CD, Reece DE, Phillips GL, et al. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Antimicrob Agents Chemother 1991; 35:2246-52.
25. Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989;149:1777-81.
26. Farber BF, Moellering JR. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23:138-41.
27. Rybak MJ, Albrecht LS, Boike SC, Chandrasekan PH. Nephrotoxicity of vancomycin alone and with an aminoglycoside. J Antimicrob Chemother 1990;25: 679-87.
28. Vance-Bryan K, Rotschafer JC, Gilliland SS, Rodvold KA, Fitzgerald CM, Guay DRP. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. J Antimicrob Chemother 1994;33:811-21.
29. Calvo MV, Del Val MP, Alvarez MM, Dominguez-Gil A. Decision analysis to assess cost-effectiveness of low-osmolality contrast medium for intravenous urography. Am J Hosp Pharm 1992;49:577-84.
30. Eisenberg JM, Koffer H, Glick HA, Connel ML, Larrye EL, Talbot GH, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987;107:900-9.
31. O'Hanley P, Easaw J, Rugo H, Easaw S. Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am J Med 1989;87:605-13.